TASLY(SH:600535) Jin Rong Jie·2025-12-26 12:08Core Viewpoint - The "Qihang·2025 Financial Summit" held in Beijing recognized Tianjin Tianshili as the winner of the "Excellence Award in the Pharmaceutical and Biological Industry," highlighting its achievements in high-quality development and innovation in the pharmaceutical sector [1][4]. Group 1: Award and Recognition - The "Jinzhi Award" aims to set benchmarks for high-quality development, guiding listed companies to focus on their core businesses and innovate continuously [3]. - The award recognizes companies that lead high-quality development in the pharmaceutical and biological industry, emphasizing innovation, clinical value transformation, and health security [3][4]. - Tianjin Tianshili's receipt of the award reflects industry acknowledgment of its core competitiveness and high-quality development results [4][6]. Group 2: Financial Performance - In the first three quarters of 2025, Tianjin Tianshili achieved pharmaceutical industrial revenue of 5.709 billion yuan, maintaining a steady growth trend [4]. - The net profit attributable to shareholders reached 984 million yuan, representing a year-on-year increase of 16.88%, indicating improved profitability [4]. Group 3: Innovation and R&D - Innovation is the core driving force behind Tianjin Tianshili's high-quality development, with a focus on building a dual-engine R&D system for innovative traditional Chinese medicine and biopharmaceuticals [4][5]. - The company has 31 innovative drugs in its pipeline, with nearly 20 traditional Chinese medicines in late clinical stages, showcasing its long-term innovation potential [5]. - Key products include a PD-L1/VEGF dual antibody that is undergoing clinical trials, which may lead to breakthroughs in cancer treatment [5]. Group 4: Future Outlook - The award serves as a recognition of past achievements and reinforces confidence in Tianjin Tianshili's dual-engine innovation strategy and future growth prospects [6]. - The company plans to deepen investment in innovation, accelerate the conversion of pipeline results, and optimize its core business layout to contribute to public health and the upgrade of the biopharmaceutical industry [6].